It is reported that actinic keratosis has an average recurrence rate of 24% 12 months after treatment. Summary Actinic ...

As a result, it is anticipated that the prevalence of actinic keratosis disease and the utilization of topical treatment solutions for actinic keratosis will increase. As a consequence of this ...

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

Immunotherapy. 2012;4(9):939-945. The percentage of patients achieving complete clearance of their AKs in the 5-FU group was 19, 28.2 and 52.6% in the 1-, 2- and 4-week treatment groups, respectively.

With actinic keratosis (AK) diagnoses on the rise ... Early diagnosis and treatment are imperative, as around 60% of squamous cell carcinoma (SCC) cases – one of the most common forms of ...

Dermatological Surgery and Keratosis represents an essential area in skin care, in particular to address pathologies and lesions that can compromise the health or aesthetics of the skin.

The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs ...

Immunotherapy. 2012;4(9):939-945. Potential reasons for the observed improvement in outcomes in vehicle groups include the natural regression of AK lesions, variation in investigator-determined ...

The study also indicated that patients with advanced actinic keratosis responded more favourably to the treatment than those with less severe forms. Based on these findings, the upcoming Phase IIb ...